Asset profile
ARO-RAGE
RNA / oligonucleotide
Evidence outlook · lead readout
NCT05276570 · Asthma
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05276570: The study randomized 127 participants to ARO-RAGE or placebo and used triple blinding of participants, care providers, and investigators. However, the primary safety endpoint has no posted results, so whether the primary comparison was favorable or statistically significant cannot be determined.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
December 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.